RVTY Stock Overview
Provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 3/6 |
Past Performance | 1/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Revvity, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$108.65 |
52 Week High | US$131.96 |
52 Week Low | US$79.50 |
Beta | 1.08 |
1 Month Change | 1.25% |
3 Month Change | 3.57% |
1 Year Change | -8.90% |
3 Year Change | -27.90% |
5 Year Change | 13.95% |
Change since IPO | 3,180.00% |
Recent News & Updates
Recent updates
Is Revvity (NYSE:RVTY) Using Too Much Debt?
Jun 10Why We're Not Concerned About Revvity, Inc.'s (NYSE:RVTY) Share Price
Apr 03Revvity: Enter Now As Reorganization Takes Shape
Mar 21We Think Revvity (NYSE:RVTY) Can Stay On Top Of Its Debt
Feb 28Investors Can Find Comfort In Revvity's (NYSE:RVTY) Earnings Quality
Feb 13Should You Think About Buying Revvity, Inc. (NYSE:RVTY) Now?
Jan 19An Intrinsic Calculation For Revvity, Inc. (NYSE:RVTY) Suggests It's 49% Undervalued
Jan 04Revvity: More Than A Name Change Is Needed For PerkinElmer
Dec 29Why We're Not Concerned About Revvity, Inc.'s (NYSE:RVTY) Share Price
Dec 20Is Revvity (NYSE:RVTY) Using Too Much Debt?
Oct 07Revvity: Recent Investments, Acquisitions, Not Pulling Economic Weight (Rating Downgrade)
Oct 04At US$108, Is Revvity, Inc. (NYSE:RVTY) Worth Looking At Closely?
Sep 22An Intrinsic Calculation For Revvity, Inc. (NYSE:RVTY) Suggests It's 40% Undervalued
Aug 17Revvity: New Name - But New Investment Outlook? Reiterate Buy
Jul 18Revvity (NYSE:RVTY) Seems To Use Debt Quite Sensibly
Jul 03What Does Revvity, Inc.'s (NYSE:RVTY) Share Price Indicate?
Jun 17Calculating The Fair Value Of Revvity, Inc. (NYSE:PKI)
May 16We Think PerkinElmer (NYSE:PKI) Can Stay On Top Of Its Debt
Mar 28When Should You Buy PerkinElmer, Inc. (NYSE:PKI)?
Mar 13PerkinElmer Q4 2022 Earnings Preview
Feb 13A Look At The Intrinsic Value Of PerkinElmer, Inc. (NYSE:PKI)
Feb 10PerkinElmer: Capital Budgeting A Key Factor To The Investment Debate
Jan 31Danaher earnings weigh on other life sciences tools, services companies
Jan 24PerkinElmer says Q4 results will meet or exceed prior guidance
Jan 09PerkinElmer (NYSE:PKI) Has A Pretty Healthy Balance Sheet
Dec 27Is It Time To Consider Buying PerkinElmer, Inc. (NYSE:PKI)?
Dec 12PerkinElmer receives FDA approval for EONIS assay for spinal muscular atrophy in newborns
Nov 14PerkinElmer reports mixed Q3 earnings, initiates Q4 and updates FY22 pro forma guidance
Nov 08PerkinElmer, Inc.'s (NYSE:PKI) Intrinsic Value Is Potentially 48% Above Its Share Price
Oct 28Shareholder Returns
RVTY | US Life Sciences | US Market | |
---|---|---|---|
7D | -2.0% | -2.6% | 1.2% |
1Y | -8.9% | -0.9% | 20.6% |
Return vs Industry: RVTY underperformed the US Life Sciences industry which returned -0.4% over the past year.
Return vs Market: RVTY underperformed the US Market which returned 20.5% over the past year.
Price Volatility
RVTY volatility | |
---|---|
RVTY Average Weekly Movement | 3.5% |
Life Sciences Industry Average Movement | 7.0% |
Market Average Movement | 5.8% |
10% most volatile stocks in US Market | 15.5% |
10% least volatile stocks in US Market | 2.9% |
Stable Share Price: RVTY has not had significant price volatility in the past 3 months.
Volatility Over Time: RVTY's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1937 | 11,500 | Prahlad Singh | www.revvity.com |
Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.
Revvity, Inc. Fundamentals Summary
RVTY fundamental statistics | |
---|---|
Market cap | US$13.66b |
Earnings (TTM) | US$183.35m |
Revenue (TTM) | US$2.73b |
73.1x
P/E Ratio4.9x
P/S RatioIs RVTY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
RVTY income statement (TTM) | |
---|---|
Revenue | US$2.73b |
Cost of Revenue | US$1.21b |
Gross Profit | US$1.51b |
Other Expenses | US$1.33b |
Earnings | US$183.35m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 1.49 |
Gross Margin | 55.50% |
Net Profit Margin | 6.73% |
Debt/Equity Ratio | 49.4% |
How did RVTY perform over the long term?
See historical performance and comparisonDividends
0.3%
Current Dividend Yield19%
Payout RatioDoes RVTY pay a reliable dividends?
See RVTY dividend history and benchmarksRevvity dividend dates | |
---|---|
Ex Dividend Date | Jul 19 2024 |
Dividend Pay Date | Aug 09 2024 |
Days until Ex dividend | 33 days |
Days until Dividend pay date | 54 days |
Does RVTY pay a reliable dividends?
See RVTY dividend history and benchmarks